Rifaldin

Rifampicin

Method of action: Antiepile, Antimiycobacterials, Anti-Tuberculosis, Bactericidal

Treatment option: Legionnaires Disease, Brucellosis, Influenza, Infection, Meningitis, Pneumonia, Leprosy, Anthrax, Trachoma, Tuberculosis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rifaldin

Property	Description
Active ingredient	Rifampicin
Form	Capsules, Powder for Injection, Oral Suspension
Pharmacological class	Ansamycin Antibiotic, Antimycobacterial Agent
General purpose	Eliminating persistent bacterial pathogens
Origin	Semisynthetic (derived from Rifamycin B)

What Type of Medicine is Rifaldin and How is it Classified?

Rifaldin is a potent, prescription-only antimicrobial agent whose active ingredient is Rifampicin. It is fundamentally classified as a broad-spectrum antibiotic and, more specifically, belongs to the unique Ansamycin class of antibacterial drugs. The efficacy of this classification is clinically recognized for its activity against resilient pathogens.

This classification identifies Rifaldin as a powerful therapeutic option used against highly persistent bacterial threats, including Mycobacterium species. Due to its consistent efficacy and critical role in treating major global diseases, Rifampicin is designated as an essential medicine by the World Health Organization (WHO), underscoring its established importance in public health systems worldwide.

Composition, Origin, and Available Forms

The core compound in Rifaldin, Rifampicin, is a semisynthetic derivative of the naturally occurring substance Rifamycin B. The drug is supplied in multiple dosage forms to facilitate comprehensive patient care, including oral capsules and a powder for injection for intravenous use. This versatility allows medical teams to address the needs of adult and pediatric patients alike.

While Rifaldin contains a single active ingredient, its primary application involves combination therapy, distinguishing it from antibiotics typically used alone for simple infections. This multi-drug strategy is necessary to inhibit the rapid emergence of bacterial resistance.

General Therapeutic Purpose and Foundational Action

The general purpose of Rifaldin is its crucial involvement as a first-line agent in the management of specific, resilient infectious threats. A typical scenario involves its use as part of a multi-drug regimen when a patient is facing a systemic mycobacterial infection.

Rifampicin achieves its efficacy by exerting a bactericidal effect, which means the drug actively kills susceptible bacterial organisms, rather than merely inhibiting their growth. This potent action provides a robust foundation for starting specialized anti-infective treatment.

What side effects are possible with Rifaldin?

Possible side effects and safety information

Official regulatory documents classify the safety profile of Rifaldin (Rifampicin) based on the frequency and the physiological system affected, consistent with authoritative governmental guidelines.

Adverse Reaction Classification

The most commonly documented adverse reactions include headache, dizziness, fatigue, and gastrointestinal effects such as nausea, vomiting, diarrhea, and heartburn.

Adverse effects impacting specific organ systems are formally documented, including Hepatobiliary Disorders (potential for hepatitis and liver dysfunction), Blood and Lymphatic System Disorders (such as thrombocytopenia and hemolytic anemia), and Renal and Urinary Disorders (including rare acute renal failure).

Serious and Exposure-Related Safety Notes

The most clinically significant adverse reactions listed in regulatory texts involve severe hepatotoxicity, which can be fatal, and severe systemic hypersensitivity reactions, including anaphylaxis and severe cutaneous adverse reactions like Stevens-Johnson syndrome (SJS).

Safety data explicitly note that thrombocytopenia and acute renal failure are more frequently observed when the medicine is administered intermittently or when a daily regimen is re-initiated after an interruption.

An expected, non-pathological finding is the red-orange discoloration of all body fluids, including urine, sweat, saliva, and tears. Furthermore, official labeling advises particular caution and periodic liver function monitoring for individuals with pre-existing hepatic impairment.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Rifaldin

Overdose scope

Documented overdose presentations: Nausea, vomiting, abdominal pain, pruritus, headache, and increasing lethargy are expected soon after ingestion. A characteristic, dose-dependent brownish-red or orange discoloration (chromaturia/chromoderma) of the skin, urine, sweat, saliva, and tears will occur.

Physiological systems affected (as stated in label): The official labeling documents risk to the Hepatic System (severe toxic hepatitis, transient increases in liver enzymes and bilirubin), Cardiovascular System (hypotension, ventricular arrhythmias, sinus tachycardia), and Central Nervous System (seizures, unconsciousness).

Dose-related or exposure-related factors (if applicable): The intensity of the skin and body fluid discoloration is proportional to the amount ingested. Fatal and nonfatal acute overdoses have been reported.

Population-specific overdose notes (if applicable): Unconsciousness may occur when there is severe pre-existing hepatic disease. Facial or periorbital oedema has been specifically noted in paediatric patients. Alcohol or a history of alcohol abuse was a factor in some reported fatal and nonfatal cases.

Emergency-response statements (as written in official documents): No specific antidote is well-established for rifampicin overdosage. Intensive supportive measures should be instituted, and individual symptoms must be treated as they arise. Procedural steps may include gastric lavage (preferred over emesis), followed by activated charcoal, and active diuresis.

When immediate medical help is required (label-derived phrasing only): Urgent specialist advice must be obtained, and immediate action is required to stabilize the patient, including securing the airway and establishing adequate respiratory exchange.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents): Classified by the potential for life-threatening outcomes, including acute liver failure and cardiac events.

Regulatory basis (EMA / FDA / etc.): Overdose information is consistently detailed in FDA Prescribing Information and EMA-aligned Summary of Product Characteristics.

Overdose-context constraints (as defined in official documents): Management is strictly supportive and symptomatic due to the absence of a specific neutralizing agent.

Resulting Overdose Structure

Official overdose statements:

The official labeling requires the institution of intensive supportive measures and urgent specialist advice upon suspected overdosage due to the high risk of severe systemic toxicity.
Regulatory documents confirm that there is no specific neutralizing antidote available for Rifampicin overdosage.
Life-threatening outcomes, including severe hepatotoxicity, seizures, and cardiovascular collapse (hypotension, arrhythmias), are explicitly documented in regulatory sources as potential consequences.

Connection to the overall overdose profile (2–4 sentences): The official regulatory profile defines a scenario of potential severe multi-system toxicity, characterized by distinctive external signs and critical internal organ damage. This profile mandates that immediate medical attention must be sought to implement supportive procedures, such as gastric decontamination, and to manage potentially fatal complications in the cardiovascular and hepatic systems, underscoring the necessity for urgent, non-specific emergency care.

Therapeutic Uses of Rifaldin

Rifaldin is a widely used medication applied in specific clinical settings to manage severe bacterial diseases and assist in preventative care.

This medication is typically used in conjunction with other antibiotics and plays a role in the management of bacterial diseases. Rifaldin (Rifampicin) helps manage symptoms related to systemic imbalance that often accompany chronic infections by addressing the infectious agent. It is applied across therapeutic domains where additional symptomatic support is needed.

The primary therapeutic domains include the management of Tuberculosis (TB) and Leprosy (Hansen's disease), as well as short-term chemoprophylaxis to manage the potential spread of certain pathogens like Neisseria meningitidis and Haemophilus influenzae to close contacts. It helps address symptom clusters that may become intense or disruptive, such as prolonged fevers, night sweats, and systemic weakness.

A key patient benefit is that it offers symptomatic relief that helps patients cope more steadily with difficult episodes, supports the overall management of the infectious process.

“It plays a role in managing symptoms that interfere with daily comfort during intense periods of infectious illness.”

Quick Fact: Relief for Systemic Imbalance

Rifaldin is used for managing conditions marked by heightened physiological stress, assists with managing the risk of severe disease development for both symptomatic patients and asymptomatic carriers, and may help support a sense of stability.

Regulatory References

NIH MedlinePlus Drug Information on Rifampin

Eligibility and Restrictions for Use

Official Population Eligibility for Rifaldin (Rifampicin)

The official regulatory documentation defines specific populations who are eligible to use Rifaldin and those for whom use is strictly prohibited or restricted.

Populations Who Cannot Use Rifaldin (Contraindications)

Use of Rifaldin is absolutely contraindicated in patients who have a known history of hypersensitivity or allergic reaction to rifampicin or any other rifamycin drug. Additionally, the medicine must not be used in the presence of jaundice or severe liver impairment. Rifaldin is also strictly contraindicated when administered concurrently with specific strong CYP3A4-sensitive medications, including Lurasidone and certain HIV Protease Inhibitors (such as Ritonavir-boosted Saquinavir), as specified in official labeling.

Restricted and Conditional Use

Age Eligibility

Rifaldin is established for use in adult and pediatric populations for its approved indications. However, caution is advised for geriatric (older adult) patients, especially if there is evidence of impaired liver function. Caution is also specifically recommended for children under two years of age when the drug is used in combination regimens.

Organ and Comorbidity-Based Restrictions

Patients with impaired liver function require close medical supervision and dose restrictions. While no dose adjustment is required for patients with normal renal function receiving standard doses, caution is advised if the daily dosage exceeds 600 mg. Use in patients with porphyria requires extreme caution due to the drug's effect on enzyme induction.

What should I know about interactions with other medicines?

The interaction profile of Rifaldin (Rifampicin) is defined by its strong, documented activity as a metabolic enzyme inducer, an action that significantly accelerates the body’s elimination of numerous other medicinal products. Rifaldin is a potent inducer of multiple Cytochrome P-450 (CYP) enzymes, including CYP3A4, and the P-glycoprotein (P-gp) transport system. This profound pharmacokinetic interaction results in a substantial decrease in the plasma concentrations of many co-administered drugs, often leading to a documented loss of therapeutic effectiveness.

Formal Restrictions and Contraindications

Co-administration is formally prohibited with specific agents due to the severe interaction risk. These combinations, documented in regulatory labels, include Lurasidone, Voriconazole, and several HIV and Hepatitis C antiviral medications, such as the Saquinavir/Ritonavir combination. The induced clearance effect reduces the efficacy of a wide range of drug classes, including systemic hormonal contraceptives, certain anticoagulants (like Warfarin), immunosuppressants, and antifungals.

Timing and Substance Interactions

Specific conditions for administration are mandated to manage interactions. To ensure adequate blood levels, the co-administration of p-Aminosalicylic acid (PAS) must be administered at least eight hours apart from Rifaldin. Concomitant use of aluminum-containing antacids may reduce Rifampicin absorption and must be separated by at least one hour. Additionally, a pharmacodynamic risk of increased hepatotoxicity is documented, leading to an official advisory to restrict alcohol consumption during treatment.

Mechanism of Action

Rifaldin's pharmacodynamic action is defined by two selective mechanisms: the inhibition of bacterial life processes and the modulation of host metabolism.

Selective Blockade of Bacterial Gene Transcription

Rifaldin exerts its primary mechanism by non-competitively inhibiting bacterial DNA-dependent RNA Polymerase (RNAP), specifically by binding to the enzyme's beta-subunit. This interaction physically obstructs the path of the nascent RNA chain, immediately halting the synthesis of all essential bacterial proteins. This rapid molecular blockade leads directly to a bactericidal effect on susceptible organisms.

Modulation of Host Metabolic Clearance Systems

Separately, Rifaldin acts as an agonist for human nuclear receptors, notably the Pregnane X Receptor (PXR), located primarily in liver and gut cells. Activation of PXR triggers the increased transcription and production of metabolic enzymes, such as those in the Cytochrome P450 (CYP) family. This mechanism accelerates hepatic metabolic pathways, resulting in a faster clearance rate for various co-administered compounds and endogenous substances.

Mechanistic Limitation

The RNAP-inhibition mechanism is highly vulnerable to spontaneous bacterial evolution. A single point mutation in the rpoB gene can drastically alter the RNAP binding site. This mechanistic limitation rapidly leads to resistance, and the mechanism exhibits low functional resilience when applied without co-agents.

Dosage and Administration Information

How Rifaldin is Used: Official Administration Guidelines

Rifaldin (Rifampicin) is administered according to established protocols that dictate the route, dose, and frequency. The medicine is available for Oral (PO) use as capsules or suspension, or for Intravenous (IV) Infusion when oral intake is impaired. The IV form is for infusion only and must not be given via intramuscular or subcutaneous injection.

Administration and Dosing

For major infectious diseases, Rifaldin is mandatorily used in combination with at least one other antimicrobial agent to prevent the rapid development of bacterial resistance. Oral doses should typically be taken on an empty stomach (one hour before or two hours after a meal) to optimize the absorption profile.

Indication	Standard Adult Dose	Frequency and Duration
Tuberculosis	600 mg (max) daily, often weight-based at 10 mg/kg	Once daily, typically 6–9 months
Prophylaxis (Meningococcal carrier state)	600 mg	Twice daily for 2 days

Population-Specific Use

Dosing for pediatric patients is strictly weight-based (e.g., 10 to 20 mg/kg daily) and must not exceed the adult maximum of 600 mg per day. For patients with hepatic impairment, a dose reduction is typically advised, with the daily dose not exceeding 8 mg/kg. No adjustment is generally needed for the standard dose in renal impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Rifaldin

Evidence for use in Active Tuberculosis (TB) Treatment

Research into Rifaldin's role in the management of active tuberculosis was studied through a foundational structure of Randomized Controlled Trials (RCTs) and controlled dose-ranging studies, with findings summarized through Systematic Reviews and Meta-analyses. The main study outcomes examined include measurements of the rate of bacterial population reduction (sputum sterilization) and overall treatment response measures. Research explored outcomes related to daily functioning that were measured during the defined treatment period. There is limited information regarding the clinical effects for potential higher dose levels (e.g., above 20 mg/kg). Research is ongoing to examine adjustments to the total treatment period.

Evidence for use in Leprosy (Hansen's Disease) Management

The evidence base for Rifaldin in Leprosy management includes Controlled Clinical Trials and Cluster RCTs. Research examined the drug's use in the multi-drug treatment for diagnosed Leprosy and explored the use of a single dose in prevention studies for exposed contacts. The studies monitored outcomes related to patient cure rates and the subsequent development of clinical disease in contacts. The evidence regarding single-dose prophylaxis describes a pattern observed in studies where follow-up was extended for periods up to four years, observing the subsequent manifestation of clinical disease.

Evidence for use in Chemoprophylaxis for High-Risk Contacts

Research for this use was evaluated in Randomized Controlled Trials and short-term Systematic Reviews. The primary study outcomes examined were the rate of reduction or elimination of bacterial carriage in the nose and throat and the occurrence of subsequent secondary invasive disease among contacts. Data showing patterns related to reduction of bacterial carriage were observed shortly after the drug was evaluated. A key limitation is that research has noted that the use of this drug may be associated with the development of bacterial resistance in some pathogens, which was observed in some studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Rifaldin (FAQ)

Q: What happens if I miss a dose of Rifaldin?

Patient counseling instructions state that for a forgotten dose, official guidance states the missed dose may be taken as soon as it is recalled. However, if the time is near for the next scheduled dose, the missed dose is generally skipped entirely. Regulatory guidance advises against taking two doses at the same time.

Q: Are there any specific warning signs I should look for when taking Rifaldin?

Official product information advises patients to be aware of symptoms that could suggest potential liver problems. These warning signs include unusual feelings of weakness, a loss of appetite, and persistent nausea or vomiting. If these symptoms are observed, official regulatory guidance indicates the need for prompt medical evaluation.

Q: Why are routine blood tests sometimes needed while on Rifaldin?

Regulatory guidelines describe the need for routine blood tests primarily to monitor for potential unwanted effects on the body. This monitoring is specifically focused on checking for signs of liver dysfunction, known as hepatotoxicity, and certain blood disorders, or hematologic abnormalities.

Q: Does Rifaldin affect my ability to drive or operate machinery?

The official list of possible side effects includes symptoms such as dizziness, confusion, and trouble with coordination. Regulatory documents describe the need for caution when driving or operating machinery if these effects are experienced.

Q: What pain relievers should I avoid while using Rifaldin?

Rifaldin is described in regulatory sources as an enzyme inducer, meaning it can accelerate the body's clearance rate of many other medicines. This effect is known to reduce the amount of certain common pain relievers, like acetaminophen and acetylsalicylic acid, in the bloodstream. This significant interaction theme is officially documented.

Q: Does Rifaldin interact with any common vitamins or supplements?

Official patient information sometimes notes that supplementation with pyridoxine, also known as Vitamin B6, is noted as potentially useful for some patients taking this drug. This is mentioned in the context of general management, rather than a specific interaction warning.

Q: Does Rifaldin work for viral infections?

Regulatory documents classify Rifaldin as a powerful antibiotic and antimycobacterial agent. Its therapeutic purpose is stated to eliminate susceptible bacterial organisms. It is not indicated for the treatment of viral infections.

Q: What is the difference between Rifaldin and rifampin?

The core active compound is called rifampicin, which is the official international nonproprietary name. In the United States, this compound is often referred to as rifampin. Rifaldin is one of the brand names under which this rifampicin medication has been marketed.

Q: Is Rifaldin safe for people with diabetes?

Official documentation includes precautions regarding the use of the drug in patients with existing medical conditions like diabetes mellitus. It is noted that patients with diabetes may experience increased difficulty in controlling their blood sugar levels while using the drug.

Q: Is there a generic version of Rifaldin available?

Yes, regulatory sources confirm that the active ingredient, rifampicin, is available in generic form. The generic product is often marketed under the names rifampicin or rifampin.

Q: What are the official safety classifications of Rifaldin?

Rifaldin belongs to the Rifamycin derivative class of drugs. Regarding use during pregnancy, official classification by the Australian Therapeutics Goods Administration (TGA) has designated the drug as Category C, which signifies that the drug may cause suspected harmful, but often reversible, effects on the fetus.

Q: Is Rifaldin safe to use during pregnancy?

According to official labeling, use of this drug during pregnancy is reserved for situations where the potential benefit is judged to outweigh the potential risks to the developing fetus. Use in the last few weeks of pregnancy has been associated with reports of bleeding disorders in both the mother and the newborn.

How should Rifaldin be stored and disposed of?

Official Storage and Disposal Instructions

Rifaldin capsules must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted short excursions to 30 C (86 F). The medication must be protected from excess heat and moisture.

Container and Protection Rules

It is required to keep Rifaldin in the container it came in and ensure the cap remains tightly closed. For safety, the container must have a locked safety cap and be stored out of the sight and reach of children in a secure, elevated location.

Disposal of Unused Product

Unused or expired Rifaldin should be disposed of by following instructions for a drug take-back program, if one is available in the area. If a take-back program is not accessible, individuals must consult local regulatory guidance for the proper method of discarding the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Brazil

Spain

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z